ReviewACS chemical neuroscience2014
Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders.
Review in ACS chemical neuroscience, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06662526 (Trace Lithium Dosage for Prevention of Cognitive Declining in Patients with Mood Illnesses), which is not on this map. Cited by 153 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Trace Lithium Dosage for Prevention of Cognitive Declining in Patients with Mood Illnesses: a Randomized Double Blind Placebo Controlled Trial
Who cites it
153 citing papers in PubMed, 3 syntheses or guidelines pooled it, 311 citations in OpenAlex.
- [Schizophrenia and bipolar disorder : Treatment of cognitive impairments].Der Nervenarzt · 2018Pooled it
- Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials.Neurology · 2017Pooled it
- History of Bipolar Disorder and the Risk of Dementia: A Systematic Review and Meta-Analysis.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2017Pooled it
- Lithium for Radiation-Induced Damage in Pediatric Brain Tumors: Preclinical Evidence and Clinical Perspectives.Journal of clinical medicine · 2026Review
- Psychotropic Drugs: A Promising Non-Antibiotic Agent to Combat Multi-Drug-Resistant Microorganisms.Drug development research · 2026Review
- Lithium as a Potential Senostatic Agent in Central Nervous System Aging and Bipolar Disorder.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Lithium as a Potential Neuroprotective Strategy in Glaucoma: Mechanisms and Therapeutic Perspectives.Biomolecules · 2026Review
- Chronic Lithium Exposure Reshapes PI3K-mTOR-linked Proteostatic Networks in the Hippocampus of an Alzheimer's Disease Mouse Model.Molecular neurobiology · 2026Article
- The role of metabolic health in neurostructural and cognitive alterations in bipolar disorders.Psychological medicine · 2026Article
- Dysregulation of the Tau-Microtubule-End-Binding Protein Axis in Alzheimer's Disease and Related Tauopathies.International journal of molecular sciences · 2026Review
- Article
- Association of Lithium Exposure With Alzheimer's Disease: A Propensity Score-Matched Cohort Study.Cureus · 2026Article
- Lithium chloride suppresses ferroptosis of induced pluripotent stem cells with ApoE4/E4 from a sporadic Alzheimer's disease patient.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Review
- The spectrum of bipolar disorder in older adults.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Lithium as a disease-modifying therapy for Parkinson's disease: mechanisms, preclinical evidence, and clinical prospects.Clinical parkinsonism & related disorders · 2026Review
- Autophagy and Neuropsychiatric Disorders: Unraveling Molecular Mechanisms and Signaling Pathways.CNS & neurological disorders drug targets · 2026Review
- Mental health and gut-brain crosstalk: implications for depression and Alzheimer's disease.Neuroscience applied · 2026Review
- Lithium-Charged Gold Nanoparticles: A New Powerful Tool for Lithium Delivery and Modulation of Glycogen Synthase Kinase 3 Activity.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Mechanisms of neurotoxicity of fluoride or aluminum: implications for neurodegenerative disease risk.Current research in toxicology · 2026Review
93 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lithium is a well-established therapeutic option for the acute and long-term management of bipolar disorder and major depression. More recently, based on findings from translational research, lithium has also been regarded as a neuroprotective agent and a candidate drug for disease-modification in certain neurodegenerative disorders, namely, Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and, more recently, Parkinson's disease (PD). The putative neuroprotective effects of lithium rely on the fact that it modulates several homeostatic mechanisms involved in neurotrophic response, autophagy, oxidative stress, inflammation, and mitochondrial function. Such a wide range of intracellular responses may be secondary to two key effects, that is, the inhibition of glycogen synthase kinase-3 beta (GSK-3β) and inositol monophosphatase (IMP) by lithium. In the present review, we revisit the neurobiological properties of lithium in light of the available evidence of its neurotrophic and neuroprotective properties, and discuss the rationale for its use in the treatment and prevention of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.